Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis

International Journal of Pharmaceutics

Volumn 398, Issue 1-2, 2010, Pages 165-178

  Pople, Pallavi V ^a   Singh, Kamalinder K ^a  

^a SNDT WOMEN S UNIVERSITY   (India)

Author keywords

Drug targeting; Lipid nanoparticles; Skin penetration enhancement; Tacrolimus

Indexed keywords

LIPID; LIPID NANOPARTICLE; NANOPARTICLE; POLIDOCANOL; POLOXAMER; POLYGLYCEROL DIOLEATE; POLYSORBATE 80; SORBITAN OLEATE; SURFACTANT; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACCUMULATION; DRUG PENETRATION; DRUG SAFETY; DRUG STABILITY; ENCAPSULATION; EXCIPIENT COMPATIBILITY; EXPERIMENTAL RABBIT; GEL; HYDROPHILICITY; HYDROPHOBICITY; INFRARED SPECTROSCOPY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SKIN IRRITATION; SKIN PENETRATION; VISCOSITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; DERMATITIS, ATOPIC; DRUG DELIVERY SYSTEMS; ERYTHEMA; RABBITS; RATS; SKIN ABSORPTION; SWINE; TACROLIMUS; TREATMENT OUTCOME;

EID: 77956226428     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.008     Document Type: Article

References (70)

1. Adamich, M., Bach, D.T., 21 December 1984. Method for manufacturing liposomes. US Patent 4,622,188.
2. Al-Haj N., Rasedee A. Solid lipid nanoparticles preparation and characterization. Int. J. Pharmacol. 2009, 5(1):90-93.
3. Beckette A.H., Stenlake J.B. Infrared spectrophotometry. Practical Pharmaceutical Chemistry 1988, Athlone Press, UK, pp. 379-407. 4th ed. Part two.
4. Bhalekar M.R., Pokharkar V., Madgulkar A., Patil N., Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech. 2009, 10(1):289-296.
5. Boguniewicz M., Fiedler V.C., Raimer S. A randomized vehicle-controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children. J. Allergy Clin. Immunol. 1998, 102:637-644.
6. Borgia S.L., Regehly M., Sivaramakrishnan R., Mehnert W., Korting H.C., Danker K., Roder B., Kramer K.D., Schafer-Korting M. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J. Control. Rel. 2005, 110:151-163.
7. Borhade V., Nair H., Hegde D. Design and evaluation of Self-Microemulsifying Drug Delivery System (SMEDDS) of tacrolimus. AAPS PharmSciTech. 2008, 9(1):13-21.
8. Cheer S.M., Plosker G.L. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am. J. Clin. Dermatol. 2001, 2:389-406.
9. Choi D., Cho H. Effect of tacrolimus derivatives on immunosuppression. Arch. Pharm. Res. 2009, 32(4):549-557.
10. De Vringer, T., 16 September 1997. Topical preparation containing a suspension of solid lipid particles. US Patent 5,667,800.
11. Draize J., Woodard G., Calvery H. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 1944, 82:377-390.
12. El-kamel A.H., Al-fagih I.M., Alsarra I.A. Testosterone solid lipid microparticles for transdermal drug delivery. Formulation and physicochemical characterization. J. Microencaps. 2007, 24(5):457-475.
13. Erdogan M., Wright J.R., McAlister V.C. Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br. J. Dermatol. 2002, 146:964-967.
14. Fang J.Y. Nano- or submicron-sized liposomes as carriers for drug delivery. Forum Chang Gung Med. J. 2006, 29:358-362.
15. Freitas C., Muller R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 1999, 47:125-132.
16. Furue M., Terao H., Rikishisa K. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br. J. Dermatol. 2003, 148:128-133.
17. Guterres S.S., Alves M.P., Pohlmann A.R. Polymeric nanoparticles. nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights 2007, 2:147-157.
18. Honary S., Chaigani M., Majidian A. The effect of particle properties on the semisolid spreadability of pharmaceutical pastes. Indian J. Pharm. Sci. 2007, 69(3):423-426.
19. Hou D., Xie C., Huang K., Zhu C. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003, 24:1781-1785.
20. Jenning V., Gysler A., Schafer-Korting M., Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 2000, 49:211-218.
21. Jenning V., Schäfer-Korting M., Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Control. Rel. 2000, 66:115-126.
22. Jores K., Mehnert W., Mader K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm. Res. 2003, 20(8):1274-1283.
23. Kang S., Lucky A.W., Pariser D., Lawrence I., Hanifin J.M. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J. Am. Acad. Dermatol. 2001, 44:58-64.
24. Kaparissides, C., Alexandridou, S., Kotti, K., Chaitidou, S., 2006. Recent advances in novel drug delivery systems. J. Nanotechnol. Online,
25. Kudla, R.M., 31 December 1979. Topical ointment. US Patent 4,279,901.
26. Lamprecht A., Yamamoto H., Takeuchi H., Kawashima Y. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J. Control. Rel. 2005, 104(2):337-346.
27. Lauerma A.I., Maibach H.I. Topical FK506-clinical potential or laboratory curiosity?. Dermatology 1994, 188(3):173-176.
28. Lee G., Lee D., Kang K., Lee C., Pyo H., Choi T. Preparation and characterization of Bis-ethylhexyloxyphenolmethoxyphenyltriazine (BEMT) loaded solid lipid nano-particles (SLN). J. Ind. Eng. Chem. 2007, 13(7):1180-1187.
29. Lee M.J., Straubinger R.M., Jusko W.J. Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK 506) in rats. Pharm. Res. 1995, 12(7):1055-1059.
30. Liu J., Hu W., Chen H., Ni Q., Xu H., Yang A. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int. J. Pharm. 2007, 328:191-195.
31. Loice K., Jayachandra R., Prado R., Kolot A., Armstrong C., Ansel J., Singh M. In vitro and in vivo evaluation of topical formulations of Spantide II. AAPS PharmSciTech. 2005, 6(4):E565-E572. (Article 71).
32. Maia C.S., Mehnert W., Schafer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocortecoids. Int. J. Pharm. 2000, 196:165-167.
33. Manconi M., Sinico C., Valenti D., Lai F., Fadda A. Niosomes as carriers for tretinoin. III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int. J. Pharm. 2006, 311(1-2):11-19.
34. Morrison R.T., Boyd R.N. Spectroscopy and structure. Organic Chemistry 1992, Prentice-Hall, Inc., pp. 590-597. sixth ed.
35. Mozafari M.R. Liposomes: an overview of manufacturing techniques. Cell. Mol. Biol. Lett. 2005, 10(4):711-719.
36. Mühlen A., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45:149-155.
37. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
38. Murthy R.S.R., Vivek K., Reddy H. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of Olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2007, 8(4):E1-E9. (Article 83).
39. Nagi A., Haj A.L., Abdullah R., Ibrahim S., Bustamam A. Tamoxifen drug loading solid lipid nanoparticles prepared by hot high pressure homogenization techniques. Am. J. Pharmacol. Toxicol. 2008, 3(3):219-224.
40. Neubert R., Wohlrab W. In vitro methods for the biopharmaceutical evaluation of topical formulations. Acta Pharm. Technol. 1990, 36:197-206.
41. Norlén L., Emilson A., Forslind B. Stratum corneum swelling. Biophysical and computer assisted quantitative assessments. Arch. Dermatol. Res. 1997, 289:506-513.
42. OECD Guidelines, 2002. Test Guideline 404, Acute dermal irritation/corrosion. OECD, Paris.
43. Paller A., Eichenfeld L.F., Leung D.Y., Stewart D., Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J. Am. Acad. Dermatol. 2001, 44:47-57.
44. Pardeike J., Hommoss A., Muller R. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 2009, 366(1-2):170-184.
45. Park Y., Ryu D., Li D., Quan Q.Z., Oh D., Kim J.O., Seo Y.G., Lee Y.I., Yong C.S., Woo J.S., Choi H.G. Physicochemical characterization of Tacrolimus-loaded solid dispersion with sodium carboxylmethyl cellulose and sodium lauryl sulfate. Arch. Pharm. Res. 2009, 32(6):893-898.
46. Pople P.V., Singh K.K. Development and evaluation of topical formulation containing solid lipid nanoparticles of Vitamin A. AAPS PharmSciTech. 2006, 7(4):E1-E7. (Article 91).
47. Rubins A., Gutmane R., Valdmane N., Stevenson P., Foster C., Undre N. Pharmacokinetics of 0.1% Tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J. Invest. Dermatol. 2005, 125:68-71.
48. Ruzicka T., Assmann T., Homey B. Tacrolimus the drug for the turn of the millennium?. Arch. Dermatol. 1999, 135:574-580.
49. Ruzicka T., Bieber T., Schopf E. A short-term trial of tacrolimus ointment for atopic dermatitis. N. Engl. J. Med. 1997, 337:816-821.
50. Santoyo S., Jalón G., Ygartua P., Renedo M., Blanco-Príeto M. Optimization of topical cidofovir penetration using microparticles. Int. J. Pharm. 2002, 242(1-2):107-113.
51. Schäfer-Korting M., Mehnert W., Korting H. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev. 2007, 59(6):427-443.
52. Schwarz C., Mehnert W., Lucks J.S., Muller R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I: Production, characterization and sterilization. J. Control. Rel. 1994, 30:83-96.
53. Shahiwala A., Misra A. Studies in topical application of niosomally entrapped Nimesulide. J. Pharm. Pharm. Sci. 2002, 5(3):220-225.
54. Shivakumar H.N., Patel P.B., Desai B.G., Ashok P., Arulmozhi S. Design and statistical optimization of glipizide loaded lipospheres using response surface methodology. Acta. Pharm. 2007, 57:269-285.
55. Soukharev A.R. Stability of lipid excipients in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2007, 59:411-418.
56. Souto E.B., Wissing S.A., Barbosa C.M., Müller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 2004, 278:71-77.
57. Spergel J., Leung D. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr. Allergy Asthma Rep. 2006, 6(4):270-274.
58. Tocci M., Matkovich D., Collier K., Kwok P., Dumont F., Lin S., Degudicibus S., Siekierka J., Chin J., Hutchinson N. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. 1989, 143(2):718-726.
59. Uno T., Yamaguchi T., Li X.K., Suzuki Y., Hashimoto H., Harada Y., Kimura T., Karzui T. The pharmacokinetics of water-in-oil-in-water-type multiple emulsion of a new tacrolimus formulation. Lipids 1997, 32(5):543-548.
60. Viriyaroj A., Ritthidej G. Diazepam-glycerol behenate nanoparticles for partenteral delivery prepared by the hot homogenization process. Asian J. Pharm. Sci. 2006, 1:17-30.
61. Wang Q., Uno T. Biodegradable microshpere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. Am. J. Transplant 2004, 4:721-727.
62. Wissing S.A., Lippacher A., Muller R.H. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J. Cosmet. Sci. 2001, 52:313-324.
63. Wissing S.A., Muller R.H. The influence of the crystallinity of lipid nanoparticles on their occlusive properties. Int. J. Pharm. 2002, 242:377-379.
64. Wissing S.A., Müller R.H. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity-in vivo study. Eur. J. Pharm. Biopharm. 2003, 56:67-72.
65. Yadav V., Pandit V., Suresh S., Yadav S. Curcumin loaded palmitic acid microparticles: formulation and optimization using factorial design. InPharm. Commun. 2008, 1(1):15-18.
66. Yamamoto T., Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur. J. Dermatol. 2003, 13:471-473.
67. Yamashita K., Nakate T., Okimoto K., Ohike A., Tokunaga Y., Ibuki R., Higaki K., Kimura T. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 2003, 267(1-2):79-91.
68. Yoshida H., Tamura S., Toyoda T., Kado K., Ohnishi N., Ibuki R. In vitro release of tacrolimus from tacrolimus ointment and its speculated mechanism. Int. J. Pharm. 2004, 270:55-64.
69. Zahir H., Nand R.A., Brown K.F., Tattam B.N., Mclachlan A.J. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J. Pharmacol. Toxicol. Methods 2001, 46(1):27-35.
70. ZurMühlen A., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45(2):149-155.